Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: A case report

被引：2

作者：

Shimizu K. ^{[1
]}

Sasaki T. ^{[2
]}

Tomaru T. ^{[2
]}

Noike H. ^{[1
]}

机构：

[1] Toho University Sakura Medical Center, Department of Internal Medicine, Chiba

[2] Toho University Sakura Medical Center, Department of Clinical Functional Physiology, Chiba

来源：

Thrombosis Journal | / 14卷 / 1期

关键词：

Deep vein thrombosis; Edoxaban; Factor Xa inhibitor; Fondaparinux; Venous thromoboembolism;

D O I：

10.1186/s12959-016-0089-x

中图分类号：

学科分类号：

摘要：

Background: Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We present a case of extensive deep vein thrombosis treated using fondaparinux and edoxaban. Case presentation: A 63-year-old man with redness, pain, and swelling of the left leg lasting for more than 1 month was referred to our hospital. Ultrasonography revealed a thrombus in the left femoral vein. Computed tomographic angiography revealed clots in the distal right pulmonary artery. Thus, the anticoagulant treatment was initiated with subcutaneous injections of fondaparinux (7.5 mg) for 5 consecutive days, followed by once daily oral administration of edoxaban (60 mg). After 3 months of treatment, a regression of thrombotic clots was shown. Three months later, the remaining clots disappeared, leaving only mural thrombi; no bleeding complications were observed during the treatment period. Conclusion: The anticoagulant treatment with subcutaneous fondaparinux and subsequently with oral edoxaban was effective for treating extensive deep vein thrombosis. © 2016 The Author(s).

引用

共 20 条

[1]

Goldhaber S.Z., Bounameaux H., Pulmonary embolism and deep vein thrombosis, Lancet, 379, pp. 1835-1846, (2012)

[2]

Fuji T., Fujita S., Tachibana S., Kawai Y., A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty, J Thromb Haemost, 8, pp. 2458-2468, (2010)

[3]

Raskob G., Cohen A.T., Eriksson B.I., Puskas D., Shi M., Bocanegra T., Et al., Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: a randomised double-blind dose-response study, Thromb Haemost, 104, pp. 642-649, (2010)

[4]

Weitz J.I., Connolly S.J., Patel I., Salazar D., Rohatagi S., Mendell J., Et al., Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation, Thromb Haemost, 104, pp. 633-641, (2010)

[5]

Nakamura M., Miyata T., Ozeki Y., Takayama M., Komori K., Yamada N., Et al., Current venous thromboembolism management and outcomes in Japan, Circ J, 78, pp. 708-717, (2014)

[6]

Lozano F., Trujillo-Santos J., Barron M., Gallego P., Babalis D., Santos M., Et al., Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs, J Vasc Surg, 59, pp. 1362-1367, (2014)

[7]

Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., Prins M.H., Raskob G., Berg-Segers A.E., Cariou R., Leeuwenkamp O., Lensing A.W., Subcutaneous fondaprinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism, N Engl J Med, 349, 18, pp. 1695-1702, (2003)

[8]

Spyropoulos A.C., Outpatient-based treatment protocols in the management of venous thromboembolic disease, Am J Manag Care, 6, 20, pp. 1034-1044, (2000)

[9]

Buller H.R., Et al., Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, pp. 1406-1415, (2013)

[10]

Schulman S., Et al., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, pp. 764-772, (2014)

← 1 2 →